SCHEMBL849127

SCHEMBL849127

Cc1ccc(C(=O)CCc2ccc([S+](C)[O-])nc2)c(Nc2ccccc2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT6 P42226 1/20 0.37
▸ PDE4B Q07343 7/20 0.35
▸ MAPK8 P45983 1/20 0.35
▸ IGF1R P08069 1/20 0.34
▸ EGFR P00533 2/20 0.34
▸ SYK P43405 2/20 0.34
▸ ZAP70 P43403 1/20 0.34
▸ ITK Q08881 1/20 0.34
▸ RHOA P61586 1/20 0.33
▸ BTK Q06187 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC4 P56524 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC7 Q8WUI4 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ HDAC9 Q9UKV0 1/20 0.33
▸ HDAC5 Q9UQL6 1/20 0.33
▸ FFAR1 O14842 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL846959 0.84 FFAR1 (0.40) STAT6PDE4BMAPK8IGF1RSYK
SCHEMBL847744 0.84 STAT6 (0.39) STAT6PDE4BMAPK8IGF1REGFR
SCHEMBL846971 0.83 STAT6 (0.38) STAT6PDE4BMAPK8IGF1REGFR
SCHEMBL847717 0.82 KMT2A (0.42) STAT6PDE4BMAPK8EGFRBTK
SCHEMBL847737 0.81 PDE4B (0.38) STAT6PDE4BMAPK8IGF1REGFR
SCHEMBL848421 0.81 FAAH (0.41) STAT6HDAC3HDAC1HDAC2
SCHEMBL848924 0.79 CYP1A2 (0.44) —
SCHEMBL3945199 0.79 EGFR (0.34) STAT6PDE4BMAPK8EGFRITK
SCHEMBL846972 0.73 MAPT (0.36) STAT6PDE4BMAPK8EGFRSYK
SCHEMBL14617173 0.72 GAA (0.46) PDE4BMAPK8EGFRSYKZAP70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163906-B2 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO, LLC (US) 2012-04-24 — — US disclosed
EP-2148862-B1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK HOFFMANN LA ROCHE (CH) 2012-03-28 — — EP disclosed
EP-2148862-A1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. Hoffmann-Roche AG (CH) 2010-02-03 — — EP disclosed
WO-2008138920-A1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2008-11-20 — — WO disclosed
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO LLC 2008-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK MAPK9, MAPK10, MAPK1 STAT6 611/4885PDE4B 4145/4885MAPK8 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback